Bolt Biotherapeutics, Inc. (BOLT)

Every figure this model derived for BOLT, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 72,000 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 17,598,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 20,564,000 AssetsCurrent 2026-06-30
current liabilities 7,867,000 LiabilitiesCurrent 2026-06-30
equity 12,640,000 StockholdersEquity 2026-06-30
ocf -31,451,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 4,700,000 Revenues 2026-06-30
sbc 2,545,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up BOLT on one particular measure came for.

RatioValue
cash operating margin-580.83
current ratio2.92
current ratio reported2.61
deferred revenue growth-67.4
dilution pct-2.06
fcf margin-670.7
growth cv1.15
operating margin-654.53
owner earnings margin-724.85
revenue growth12.79
revenue growth per share15.16
rule of 40-641.74
sbc pct revenue54.15

What to be careful about

What this model itself distrusts about BOLT's figures. Written by the derivation as it ran, not added afterwards.